Pharma News

Caption : In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease.

Scientists investigating the evolution of the virus that causes Covid19 say that its mutation seems to be directed by human proteins that degrade it, but natural selection of the virus enables it to bounce back. The findings could help in the design of vaccines against the virus.

Caption : This illustration shows how head trauma can create microbubbles in the skull that collapse and damage nearby brain cells. Credit : Illustration by Mica Post

IMAGE: Cryo-EM reconstructions show how two different antibodies (blue) bind to the spike protein of the SARS-CoV-2 virus.

The results of the Phase I/II trial published in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.

AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack.